Fig. 3.

IL-18 enhances ADCC mediated by human NK cells against rituximab-sensitized lymphoma cells. Enriched human NK cells were incubated overnight in medium with or without 100 ng/mL IL-18 as indicated and then plated at an effector-to-target cell ratio of 10:1 with Raji cells that had been pre-treated or not with rituximab as indicated. P value for comparison of rituximab versus medium is 0.008, and for comparison of rituximab plus IL-18 versus rituximab alone or IL-18 alone is 0.03 and 0.003, respectively. Results shown represent mean ± SE of data from 3 separate experiments